LGMN has been determined to be highly expressed in many solid tumors, including colorectal cancer, breast cancer and glioblastoma (GBM), and high expression of LGMN correlated with a more metastatic phenotype, which is partially mediated by the activation of cathepsins and pro-MMP2 (Zhen et al., 2015; D’Costa et al., 2014; Sevenich and Joyce, 2014; Edgington-Mitchell et al., 2015). Here, CTSS is linked to glioblastoma.